Management

Lee A. Henderson, Ph.D., President/CEO and Founder. Dr. Henderson has developed IND enabling processes for drugs in multiple therapeutic areas including first in human IND approved treatment with a monoclonal antibody for squamous cell carcinoma in 1988. He also served on the NIH AIDS Drug Development Advisory Board. Dr. Henderson sold a division of Vybion to Meridian Biosciences in 2008 and actively manages licensing and IP. He previously managed an active research program in peptide mimetic drugs, immune suppression and mechanisms of viral envelope mediated entry.


Rick Hendrick, CFO has filled various financial management roles at US Steel, Baker Hughes, MMI Products and Hardinge, Inc. in addition to serving as a transitional CFO for a number of startup companies. His experience includes, financial forecasting, due diligence, M&A, private financings, risk management, SEC reporting and with a broad range of management and reporting responsibilities.


George T. Schneider, Board member, Treasurer and Secretary. George is actively involved in financial and operational management decisions. He has 35 years of experience in executive positions with public and private companies and currently is a lecturer in entrepreneurship at the Johnson Graduate School of Business, Cornell University.


Consultants:
John D. Noti, Ph.D., Consultant for Molecular Biology. Prior positions include the Guthrie Research Institute where he was Associate Director of Basic Research and Director of the Lab of Molecular Biology since 1990. Prior to that, Dr. Noti was a scientist at Triton Biosciences and a postdoctoral fellow at the Boyce Thompson Research Institute at Cornell University. Dr. Noti's research area is the regulation of gene expression, including the role of transcriptional regulatory genes and proteins in Leukocyte integrin gene expression during myeloid development, breast cancer integrin regulation in metastasis and the regulation of a unique muscarinic receptor involved in pain transmission. Dr. Noti has served on numerous Journal and grant review boards.


Frank Lee, Ph.D., Consultant for Biopharma and Regulatory. Previously, Frank was an Associate Investigator with the Ludwig Institute for Cancer Research and served as the GMP Operations Manager for the Cornell University/Ludwig Institute for Cancer Research Partnership at Cornell University. Frank directed the process development and manufacture of recombinant proteins for clinical trials including a P. pastoris-derived scFv molecule for colon cancer and E. coli-derived cancer-testis antigens. Prior experience includes mammalian expression vector development adenovirus replication and defective viral particles and lipooligosaccharide biosynthesis genes of pathogenic Neisseria sp.